Key Insights
The Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is experiencing rapid growth, projected to reach \$3.18 billion in 2025 and exhibiting a Compound Annual Growth Rate (CAGR) of 16.73% from 2025 to 2033. This explosive expansion is driven by several key factors. Firstly, the increasing prevalence of chronic diseases like oncology, cardiovascular diseases, and neurological disorders fuels demand for innovative cell and gene therapies. Secondly, the rising number of clinical trials and approvals for these therapies necessitates robust CDMO services for development and manufacturing. Furthermore, technological advancements in gene editing, viral vector production, and cell processing are enhancing efficiency and scalability, further accelerating market growth. Finally, the strategic partnerships and acquisitions between CDMOs and pharmaceutical companies are bolstering the industry's capacity to meet the growing demand. The market is segmented by indication (oncology being the largest segment), product (cell therapy showing significant traction), and stage of development (clinical stage representing a substantial portion of the market). North America currently holds the largest market share, attributable to the presence of major CDMO players and strong regulatory support. However, the Asia-Pacific region is expected to witness significant growth in the coming years, driven by expanding healthcare infrastructure and increasing investments in biopharmaceutical research.
The competitive landscape is characterized by a mix of large multinational CDMOs and specialized smaller companies. Key players, including Lonza, Catalent, and Charles River Laboratories, are investing heavily in expanding their capabilities to meet the evolving needs of the cell and gene therapy sector. The market is also witnessing increased consolidation, with mergers and acquisitions playing a crucial role in shaping the industry dynamics. Future growth will hinge on continuous innovation in manufacturing technologies, overcoming challenges associated with scalability and cost-effectiveness, and navigating the complex regulatory landscape governing cell and gene therapies. The focus will shift towards advanced technologies like personalized medicine and gene editing, further driving demand for sophisticated CDMO services.
Cell & Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market: A Comprehensive Report (2019-2033)
This comprehensive report provides a detailed analysis of the Cell & Gene Therapy Contract Development and Manufacturing Organization (CDMO) market, covering market dynamics, industry trends, leading segments, key players, and future growth prospects. The study period spans from 2019 to 2033, with 2025 serving as the base and estimated year. The forecast period is 2025-2033, and the historical period covers 2019-2024. This report is essential for stakeholders, investors, and industry professionals seeking to understand and capitalize on the rapidly evolving landscape of cell and gene therapy manufacturing.
Cell And Gene Therapy CDMO Market Market Dynamics & Concentration
The Cell & Gene Therapy CDMO market is characterized by a dynamic interplay of factors influencing its growth and concentration. Market concentration is currently moderate, with several large players and a growing number of smaller, specialized CDMOs vying for market share. Innovation is a key driver, fueled by advancements in gene editing technologies (e.g., CRISPR-Cas9), viral vector production, and cell culture techniques. Stringent regulatory frameworks, particularly in regions like the US and Europe, significantly impact market entry and product approvals, favoring established players with robust compliance procedures. Product substitutes are limited, although alternative manufacturing approaches might emerge, affecting the market landscape. End-user trends, particularly the rising demand for personalized medicine and advanced therapies, are significantly boosting market growth. Furthermore, M&A activities have been prevalent, with xx deals recorded during the historical period, signifying industry consolidation and expansion strategies. Key players are focusing on strategic collaborations and technology acquisitions to enhance their service portfolio and market reach. The market share of the top 5 players is estimated at approximately xx% in 2025.
Cell And Gene Therapy CDMO Market Industry Trends & Analysis
The Cell & Gene Therapy CDMO market exhibits a robust Compound Annual Growth Rate (CAGR) of xx% during the forecast period (2025-2033). This growth is driven by several key factors. Firstly, the increasing prevalence of chronic diseases like cancer, cardiovascular conditions, and genetic disorders fuels demand for innovative therapeutic options. Secondly, technological advancements in gene editing, cell engineering, and viral vector production are revolutionizing treatment modalities, necessitating specialized manufacturing capabilities. Consumer preferences are shifting towards personalized medicine, which further emphasizes the role of CDMOs. The market penetration of cell and gene therapies is steadily increasing, with a projected xx% market penetration by 2033. Competitive dynamics are characterized by intense competition among established players and emerging CDMOs. The market is witnessing a trend towards integrated service offerings, where CDMOs provide a comprehensive range of services from early development to commercial manufacturing.
Leading Markets & Segments in Cell And Gene Therapy CDMO Market
The Oncology segment currently dominates the Cell & Gene Therapy CDMO market, driven by the high prevalence of various cancer types and the substantial investment in oncology-focused research and development. North America holds a leading position due to the robust healthcare infrastructure, presence of major CDMOs, and favorable regulatory environment.
Key Drivers for Dominant Segments:
- Oncology: High prevalence of cancer, significant R&D investment, and regulatory approvals.
- North America: Robust healthcare infrastructure, presence of major CDMO players, and favorable regulatory landscape.
- Cell Therapy: Growing adoption due to its inherent advantages in treating specific diseases.
- Commercial Stage: Higher revenue generation compared to pre-clinical and clinical stages.
Dominance Analysis: The dominance of Oncology and North America is driven by several factors including high disease prevalence, substantial funding for research and development, and a well-established regulatory framework. The commercial stage demonstrates higher revenue generation due to the larger volume of treatments and higher cost of production. The market share of other indications and regions is expected to grow but remains smaller compared to the leading segments.
Cell And Gene Therapy CDMO Market Product Developments
Significant advancements in vector production technologies, cell engineering, and process automation are shaping the Cell & Gene Therapy CDMO market. Innovative technologies such as closed-system manufacturing and automation are improving efficiency, consistency, and scalability of manufacturing processes. The trend is towards developing highly flexible and adaptable manufacturing platforms to meet the diverse needs of varied cell and gene therapies. This results in competitive advantages for CDMOs that can offer tailored solutions and faster turnaround times.
Key Drivers of Cell And Gene Therapy CDMO Market Growth
Several factors are driving the growth of the Cell & Gene Therapy CDMO market. Technological advancements, especially in gene editing and viral vector production, are creating new treatment possibilities. Favorable regulatory landscapes in several countries are facilitating market entry and product approvals. Increased investments from both public and private sectors are funding research and development, expanding the pipeline of cell and gene therapies. The rising prevalence of chronic diseases along with patient preference for personalized medicine create substantial market demand.
Challenges in the Cell And Gene Therapy CDMO Market
The Cell & Gene Therapy CDMO market faces several challenges. Stringent regulatory requirements increase the cost and complexity of product development and approval. The intricate and highly specialized nature of cell and gene therapies makes manufacturing complex and costly. Supply chain issues related to raw materials and specialized equipment can impact manufacturing efficiency and cost. Intense competition among established and emerging CDMOs can put downward pressure on prices. These factors combined create hurdles for market players.
Emerging Opportunities in Cell And Gene Therapy CDMO Market
The future of the Cell & Gene Therapy CDMO market is bright, with several emerging opportunities. Advancements in gene editing technologies, such as base editing and prime editing, open new avenues for treating various diseases. Strategic partnerships between CDMOs and pharmaceutical companies will lead to faster development and commercialization of cell and gene therapies. Expansion into emerging markets with growing healthcare infrastructure creates a significant growth potential.
Leading Players in the Cell And Gene Therapy CDMO Market Sector
- The Discovery Labs
- Patheon Inc
- Wuxi Advanced Therapies
- Lonza Group
- Almac Group
- Charles River Laboratories International Inc
- Pfizer CentreOne (Note: Pfizer CentreOne is a part of Pfizer, linking to the main Pfizer site)
- PCI Pharma Services
- BIOCENTRIQ
- Catalent Inc
- FUJIFILM Diosynth Biotechnologies
- Recipharm AB
Key Milestones in Cell And Gene Therapy CDMO Market Industry
- March 2023: Porton Advanced Solutions Ltd. partnered with DanausGT Biotechnology Co., Ltd., expanding end-to-end gene and cell therapy service provision. This collaboration accelerates the development of cutting-edge therapies by combining expertise and proprietary technology.
- March 2023: Charles River Laboratories Inc. launched a Helper Plasmid to streamline AAV vector manufacturing, enhancing efficiency and simplifying production of a crucial gene therapy component.
Strategic Outlook for Cell And Gene Therapy CDMO Market Market
The Cell & Gene Therapy CDMO market is poised for substantial growth, driven by continued technological innovation, increasing investments in R&D, and rising demand for personalized therapies. Strategic partnerships, acquisitions, and expansion into new markets will be key strategies for success in this dynamic industry. The focus on improving manufacturing efficiency, scalability, and cost-effectiveness will be crucial for CDMOs to remain competitive and meet the growing demand for cell and gene therapies.
Cell And Gene Therapy Contract Development And Manufacturing Organization Market Segmentation
-
1. Product
-
1.1. Cell Therapy
- 1.1.1. Stem-cell Based
- 1.1.2. Non Stem-cell Based
- 1.1.3. Other Therapies
-
1.2. Gene Therapy
- 1.2.1. Viral Vectors
- 1.2.2. Non-viral Vectors
-
1.1. Cell Therapy
-
2. Stage
- 2.1. Pre-clinical
- 2.2. Clinical
- 2.3. Commercial
-
3. Indication
- 3.1. Oncology
- 3.2. Cardiovascular Diseases
- 3.3. Infectious Diseases
- 3.4. Genetic Diseases
- 3.5. Neurological Diseases
- 3.6. Others Indications
Cell And Gene Therapy Contract Development And Manufacturing Organization Market Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. United Kingdom
- 2.2. Germany
- 2.3. France
- 2.4. Spain
- 2.5. Italy
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. India
- 3.2. Japan
- 3.3. China
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
-
4. Middle East and Africa
- 4.1. GCC
- 4.2. South Africa
- 4.3. Rest of the Middle East and Africa
-
5. South America
- 5.1. Brazil
- 5.2. Argentina
- 5.3. Rest of South America
Cell And Gene Therapy Contract Development And Manufacturing Organization Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of 16.73% from 2019-2033 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rise In Preclinical and Clinical Activities Around Cell and Gene Therapies; Growing Burden of Genetic Diseases and Cancer; Increasing Research and Development Investment for Cell and Gene Therapy
- 3.3. Market Restrains
- 3.3.1. Limitations in Analytical Methods for Large-scale AAV Biomanufacturing; Complex Manufacturing Process and Regulatory Challenges
- 3.4. Market Trends
- 3.4.1. Neurological Disorders Segment is Expected to Hold a Significant Share Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Product
- 5.1.1. Cell Therapy
- 5.1.1.1. Stem-cell Based
- 5.1.1.2. Non Stem-cell Based
- 5.1.1.3. Other Therapies
- 5.1.2. Gene Therapy
- 5.1.2.1. Viral Vectors
- 5.1.2.2. Non-viral Vectors
- 5.1.1. Cell Therapy
- 5.2. Market Analysis, Insights and Forecast - by Stage
- 5.2.1. Pre-clinical
- 5.2.2. Clinical
- 5.2.3. Commercial
- 5.3. Market Analysis, Insights and Forecast - by Indication
- 5.3.1. Oncology
- 5.3.2. Cardiovascular Diseases
- 5.3.3. Infectious Diseases
- 5.3.4. Genetic Diseases
- 5.3.5. Neurological Diseases
- 5.3.6. Others Indications
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Middle East and Africa
- 5.4.5. South America
- 5.1. Market Analysis, Insights and Forecast - by Product
- 6. North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by Product
- 6.1.1. Cell Therapy
- 6.1.1.1. Stem-cell Based
- 6.1.1.2. Non Stem-cell Based
- 6.1.1.3. Other Therapies
- 6.1.2. Gene Therapy
- 6.1.2.1. Viral Vectors
- 6.1.2.2. Non-viral Vectors
- 6.1.1. Cell Therapy
- 6.2. Market Analysis, Insights and Forecast - by Stage
- 6.2.1. Pre-clinical
- 6.2.2. Clinical
- 6.2.3. Commercial
- 6.3. Market Analysis, Insights and Forecast - by Indication
- 6.3.1. Oncology
- 6.3.2. Cardiovascular Diseases
- 6.3.3. Infectious Diseases
- 6.3.4. Genetic Diseases
- 6.3.5. Neurological Diseases
- 6.3.6. Others Indications
- 6.1. Market Analysis, Insights and Forecast - by Product
- 7. Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by Product
- 7.1.1. Cell Therapy
- 7.1.1.1. Stem-cell Based
- 7.1.1.2. Non Stem-cell Based
- 7.1.1.3. Other Therapies
- 7.1.2. Gene Therapy
- 7.1.2.1. Viral Vectors
- 7.1.2.2. Non-viral Vectors
- 7.1.1. Cell Therapy
- 7.2. Market Analysis, Insights and Forecast - by Stage
- 7.2.1. Pre-clinical
- 7.2.2. Clinical
- 7.2.3. Commercial
- 7.3. Market Analysis, Insights and Forecast - by Indication
- 7.3.1. Oncology
- 7.3.2. Cardiovascular Diseases
- 7.3.3. Infectious Diseases
- 7.3.4. Genetic Diseases
- 7.3.5. Neurological Diseases
- 7.3.6. Others Indications
- 7.1. Market Analysis, Insights and Forecast - by Product
- 8. Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by Product
- 8.1.1. Cell Therapy
- 8.1.1.1. Stem-cell Based
- 8.1.1.2. Non Stem-cell Based
- 8.1.1.3. Other Therapies
- 8.1.2. Gene Therapy
- 8.1.2.1. Viral Vectors
- 8.1.2.2. Non-viral Vectors
- 8.1.1. Cell Therapy
- 8.2. Market Analysis, Insights and Forecast - by Stage
- 8.2.1. Pre-clinical
- 8.2.2. Clinical
- 8.2.3. Commercial
- 8.3. Market Analysis, Insights and Forecast - by Indication
- 8.3.1. Oncology
- 8.3.2. Cardiovascular Diseases
- 8.3.3. Infectious Diseases
- 8.3.4. Genetic Diseases
- 8.3.5. Neurological Diseases
- 8.3.6. Others Indications
- 8.1. Market Analysis, Insights and Forecast - by Product
- 9. Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by Product
- 9.1.1. Cell Therapy
- 9.1.1.1. Stem-cell Based
- 9.1.1.2. Non Stem-cell Based
- 9.1.1.3. Other Therapies
- 9.1.2. Gene Therapy
- 9.1.2.1. Viral Vectors
- 9.1.2.2. Non-viral Vectors
- 9.1.1. Cell Therapy
- 9.2. Market Analysis, Insights and Forecast - by Stage
- 9.2.1. Pre-clinical
- 9.2.2. Clinical
- 9.2.3. Commercial
- 9.3. Market Analysis, Insights and Forecast - by Indication
- 9.3.1. Oncology
- 9.3.2. Cardiovascular Diseases
- 9.3.3. Infectious Diseases
- 9.3.4. Genetic Diseases
- 9.3.5. Neurological Diseases
- 9.3.6. Others Indications
- 9.1. Market Analysis, Insights and Forecast - by Product
- 10. South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - by Product
- 10.1.1. Cell Therapy
- 10.1.1.1. Stem-cell Based
- 10.1.1.2. Non Stem-cell Based
- 10.1.1.3. Other Therapies
- 10.1.2. Gene Therapy
- 10.1.2.1. Viral Vectors
- 10.1.2.2. Non-viral Vectors
- 10.1.1. Cell Therapy
- 10.2. Market Analysis, Insights and Forecast - by Stage
- 10.2.1. Pre-clinical
- 10.2.2. Clinical
- 10.2.3. Commercial
- 10.3. Market Analysis, Insights and Forecast - by Indication
- 10.3.1. Oncology
- 10.3.2. Cardiovascular Diseases
- 10.3.3. Infectious Diseases
- 10.3.4. Genetic Diseases
- 10.3.5. Neurological Diseases
- 10.3.6. Others Indications
- 10.1. Market Analysis, Insights and Forecast - by Product
- 11. North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 11.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 11.1.1 United States
- 11.1.2 Canada
- 11.1.3 Mexico
- 12. Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 12.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 12.1.1 United Kingdom
- 12.1.2 Germany
- 12.1.3 France
- 12.1.4 Spain
- 12.1.5 Italy
- 12.1.6 Rest of Europe
- 13. Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 13.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 13.1.1 India
- 13.1.2 Japan
- 13.1.3 China
- 13.1.4 Australia
- 13.1.5 South Korea
- 13.1.6 Rest of Asia Pacific
- 14. South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 14.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 14.1.1 Brazil
- 14.1.2 Argentina
- 14.1.3 Rest of South America
- 15. Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Analysis, Insights and Forecast, 2019-2031
- 15.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 15.1.1 GCC
- 15.1.2 South Africa
- 15.1.3 Rest of the Middle East and Africa
- 16. Competitive Analysis
- 16.1. Global Market Share Analysis 2024
- 16.2. Company Profiles
- 16.2.1 The Discovery Labs
- 16.2.1.1. Overview
- 16.2.1.2. Products
- 16.2.1.3. SWOT Analysis
- 16.2.1.4. Recent Developments
- 16.2.1.5. Financials (Based on Availability)
- 16.2.2 Patheon Inc
- 16.2.2.1. Overview
- 16.2.2.2. Products
- 16.2.2.3. SWOT Analysis
- 16.2.2.4. Recent Developments
- 16.2.2.5. Financials (Based on Availability)
- 16.2.3 Wuxi Advanced Therapies
- 16.2.3.1. Overview
- 16.2.3.2. Products
- 16.2.3.3. SWOT Analysis
- 16.2.3.4. Recent Developments
- 16.2.3.5. Financials (Based on Availability)
- 16.2.4 Lonza Group
- 16.2.4.1. Overview
- 16.2.4.2. Products
- 16.2.4.3. SWOT Analysis
- 16.2.4.4. Recent Developments
- 16.2.4.5. Financials (Based on Availability)
- 16.2.5 Almac Group
- 16.2.5.1. Overview
- 16.2.5.2. Products
- 16.2.5.3. SWOT Analysis
- 16.2.5.4. Recent Developments
- 16.2.5.5. Financials (Based on Availability)
- 16.2.6 Charles River Laboratories International Inc
- 16.2.6.1. Overview
- 16.2.6.2. Products
- 16.2.6.3. SWOT Analysis
- 16.2.6.4. Recent Developments
- 16.2.6.5. Financials (Based on Availability)
- 16.2.7 Pfizer CentreOne
- 16.2.7.1. Overview
- 16.2.7.2. Products
- 16.2.7.3. SWOT Analysis
- 16.2.7.4. Recent Developments
- 16.2.7.5. Financials (Based on Availability)
- 16.2.8 PCI Pharma Services
- 16.2.8.1. Overview
- 16.2.8.2. Products
- 16.2.8.3. SWOT Analysis
- 16.2.8.4. Recent Developments
- 16.2.8.5. Financials (Based on Availability)
- 16.2.9 BIOCENTRIQ
- 16.2.9.1. Overview
- 16.2.9.2. Products
- 16.2.9.3. SWOT Analysis
- 16.2.9.4. Recent Developments
- 16.2.9.5. Financials (Based on Availability)
- 16.2.10 Catalent Inc
- 16.2.10.1. Overview
- 16.2.10.2. Products
- 16.2.10.3. SWOT Analysis
- 16.2.10.4. Recent Developments
- 16.2.10.5. Financials (Based on Availability)
- 16.2.11 FUJIFILM Diosynth Biotechnologies
- 16.2.11.1. Overview
- 16.2.11.2. Products
- 16.2.11.3. SWOT Analysis
- 16.2.11.4. Recent Developments
- 16.2.11.5. Financials (Based on Availability)
- 16.2.12 Recipharm AB
- 16.2.12.1. Overview
- 16.2.12.2. Products
- 16.2.12.3. SWOT Analysis
- 16.2.12.4. Recent Developments
- 16.2.12.5. Financials (Based on Availability)
- 16.2.1 The Discovery Labs
List of Figures
- Figure 1: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Breakdown (Million, %) by Region 2024 & 2032
- Figure 2: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 3: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 4: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 5: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 6: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 7: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 8: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 9: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 10: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 11: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 12: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Product 2024 & 2032
- Figure 13: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Product 2024 & 2032
- Figure 14: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Stage 2024 & 2032
- Figure 15: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Stage 2024 & 2032
- Figure 16: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Indication 2024 & 2032
- Figure 17: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Indication 2024 & 2032
- Figure 18: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 19: North America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 20: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Product 2024 & 2032
- Figure 21: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Product 2024 & 2032
- Figure 22: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Stage 2024 & 2032
- Figure 23: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Stage 2024 & 2032
- Figure 24: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Indication 2024 & 2032
- Figure 25: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Indication 2024 & 2032
- Figure 26: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 27: Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 28: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Product 2024 & 2032
- Figure 29: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Product 2024 & 2032
- Figure 30: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Stage 2024 & 2032
- Figure 31: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Stage 2024 & 2032
- Figure 32: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Indication 2024 & 2032
- Figure 33: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Indication 2024 & 2032
- Figure 34: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 35: Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 36: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Product 2024 & 2032
- Figure 37: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Product 2024 & 2032
- Figure 38: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Stage 2024 & 2032
- Figure 39: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Stage 2024 & 2032
- Figure 40: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Indication 2024 & 2032
- Figure 41: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Indication 2024 & 2032
- Figure 42: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 43: Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
- Figure 44: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Product 2024 & 2032
- Figure 45: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Product 2024 & 2032
- Figure 46: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Stage 2024 & 2032
- Figure 47: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Stage 2024 & 2032
- Figure 48: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Indication 2024 & 2032
- Figure 49: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Indication 2024 & 2032
- Figure 50: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million), by Country 2024 & 2032
- Figure 51: South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Share (%), by Country 2024 & 2032
List of Tables
- Table 1: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Region 2019 & 2032
- Table 2: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Product 2019 & 2032
- Table 3: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Stage 2019 & 2032
- Table 4: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 5: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Region 2019 & 2032
- Table 6: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 7: United States Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 8: Canada Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 9: Mexico Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 10: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 11: United Kingdom Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 12: Germany Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 13: France Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 14: Spain Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 15: Italy Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 16: Rest of Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 17: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 18: India Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 19: Japan Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 20: China Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 21: Australia Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 22: South Korea Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 23: Rest of Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 24: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 25: Brazil Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 26: Argentina Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 27: Rest of South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 28: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 29: GCC Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 30: South Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 31: Rest of the Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 32: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Product 2019 & 2032
- Table 33: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Stage 2019 & 2032
- Table 34: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 35: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 36: United States Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 37: Canada Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 38: Mexico Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 39: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Product 2019 & 2032
- Table 40: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Stage 2019 & 2032
- Table 41: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 42: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 43: United Kingdom Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 44: Germany Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 45: France Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 46: Spain Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 47: Italy Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 48: Rest of Europe Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 49: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Product 2019 & 2032
- Table 50: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Stage 2019 & 2032
- Table 51: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 52: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 53: India Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 54: Japan Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 55: China Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 56: Australia Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 57: South Korea Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 58: Rest of Asia Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 59: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Product 2019 & 2032
- Table 60: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Stage 2019 & 2032
- Table 61: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 62: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 63: GCC Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 64: South Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 65: Rest of the Middle East and Africa Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 66: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Product 2019 & 2032
- Table 67: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Stage 2019 & 2032
- Table 68: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 69: Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue Million Forecast, by Country 2019 & 2032
- Table 70: Brazil Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 71: Argentina Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 72: Rest of South America Cell And Gene Therapy Contract Development And Manufacturing Organization Market Revenue (Million) Forecast, by Application 2019 & 2032
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Cell And Gene Therapy Contract Development And Manufacturing Organization Market?
The projected CAGR is approximately 16.73%.
2. Which companies are prominent players in the Cell And Gene Therapy Contract Development And Manufacturing Organization Market?
Key companies in the market include The Discovery Labs, Patheon Inc, Wuxi Advanced Therapies, Lonza Group, Almac Group, Charles River Laboratories International Inc, Pfizer CentreOne, PCI Pharma Services, BIOCENTRIQ, Catalent Inc, FUJIFILM Diosynth Biotechnologies, Recipharm AB.
3. What are the main segments of the Cell And Gene Therapy Contract Development And Manufacturing Organization Market?
The market segments include Product, Stage, Indication.
4. Can you provide details about the market size?
The market size is estimated to be USD 3.18 Million as of 2022.
5. What are some drivers contributing to market growth?
Rise In Preclinical and Clinical Activities Around Cell and Gene Therapies; Growing Burden of Genetic Diseases and Cancer; Increasing Research and Development Investment for Cell and Gene Therapy.
6. What are the notable trends driving market growth?
Neurological Disorders Segment is Expected to Hold a Significant Share Over the Forecast Period.
7. Are there any restraints impacting market growth?
Limitations in Analytical Methods for Large-scale AAV Biomanufacturing; Complex Manufacturing Process and Regulatory Challenges.
8. Can you provide examples of recent developments in the market?
March 2023: Porton Advanced Solutions Ltd. partnered with DanausGT Biotechnology Co., Ltd. as an end-to-end gene and cell therapy service provider. Porton Advanced will provide DanausGT with comprehensive solutions, including plasmids, viruses, and cell therapy products. By combining Porton Advanced's expertise with DanausGT's proprietary CRISPR/AAV technology, the collaboration accelerated the development of cutting-edge cell and gene therapy therapeutics.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Cell And Gene Therapy Contract Development And Manufacturing Organization Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Cell And Gene Therapy Contract Development And Manufacturing Organization Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Cell And Gene Therapy Contract Development And Manufacturing Organization Market?
To stay informed about further developments, trends, and reports in the Cell And Gene Therapy Contract Development And Manufacturing Organization Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
